Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) Stock Competitors & Peer Comparison
See HROWM's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HROWM and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| RPRX | $57.97 | +2.11% | 25.7B | 11.04 | $5.25 | +1.58% |
| CORT | $114.23 | +3.12% | 12.3B | 326.37 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $91.03 | +0.90% | 8.1B | 650.21 | $0.14 | N/A |
| KNSA | $76.53 | +0.62% | 5.8B | 85.03 | $0.90 | N/A |
| TRLV | $9.08 | +3.77% | 1.5B | -21.50 | -$0.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| LTGO | $18.56 | +1.70% | 1.1B | N/A | N/A | N/A |
| CUVL | $6.74 | +0.97% | 339.9M | N/A | N/A | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
HROWM vs RPRX Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, RPRX has a market cap of 25.7B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while RPRX trades at $57.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 11.04. In terms of profitability, HROWM's ROE is -0.34%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, HROWM is less volatile compared to RPRX. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
HROWM vs CORT Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CORT trades at $114.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 326.37. In terms of profitability, HROWM's ROE is -0.34%, compared to CORT's ROE of +0.08%. Regarding short-term risk, HROWM is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
HROWM vs WBA Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas WBA's P/E ratio is -1.64. In terms of profitability, HROWM's ROE is -0.34%, compared to WBA's ROE of -0.42%. Regarding short-term risk, HROWM is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
HROWM vs LQDA Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LQDA has a market cap of 8.1B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while LQDA trades at $91.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 650.21. In terms of profitability, HROWM's ROE is -0.34%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, HROWM is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
HROWM vs KNSA Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, KNSA has a market cap of 5.8B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while KNSA trades at $76.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 85.03. In terms of profitability, HROWM's ROE is -0.34%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, HROWM is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check KNSA's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
HROWM vs TRLV Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while TRLV trades at $9.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas TRLV's P/E ratio is -21.50. In terms of profitability, HROWM's ROE is -0.34%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, HROWM is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check TRLV's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
HROWM vs HROWL Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas HROWL's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.34%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, HROWM is less volatile compared to HROWL. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check HROWL's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
HROWM vs LTGO Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LTGO has a market cap of 1.1B. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while LTGO trades at $18.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LTGO's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.34%, compared to LTGO's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check LTGO's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
HROWM vs CUVL Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CUVL has a market cap of 339.9M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CUVL trades at $6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CUVL's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.34%, compared to CUVL's ROE of N/A. Regarding short-term risk, HROWM is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check CUVL's competition here
LifeMD, Inc. (NASDAQ: LFMD)
HROWM vs LFMD Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LFMD has a market cap of 175.1M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while LFMD trades at $3.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LFMD's P/E ratio is -7.24. In terms of profitability, HROWM's ROE is -0.34%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, HROWM is less volatile compared to LFMD. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check LFMD's competition here
LifeMD, Inc. (NASDAQ: LFMDP)
HROWM vs LFMDP Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LFMDP has a market cap of 160.2M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while LFMDP trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LFMDP's P/E ratio is -724.19. In terms of profitability, HROWM's ROE is -0.34%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, HROWM is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check LFMDP's competition here
Circle8 Group, Inc. (NASDAQ: CIRC)
HROWM vs CIRC Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CIRC has a market cap of 63M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CIRC trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CIRC's P/E ratio is -1.59. In terms of profitability, HROWM's ROE is -0.34%, compared to CIRC's ROE of +0.00%. Regarding short-term risk, HROWM is less volatile compared to CIRC. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check CIRC's competition here
Rite Aid Corporation (NYSE: RAD)
HROWM vs RAD Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas RAD's P/E ratio is -0.05. In terms of profitability, HROWM's ROE is -0.34%, compared to RAD's ROE of +2.76%. Regarding short-term risk, HROWM is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
HROWM vs GLTO Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas GLTO's P/E ratio is -1.78. In terms of profitability, HROWM's ROE is -0.34%, compared to GLTO's ROE of -1.22%. Regarding short-term risk, HROWM is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check GLTO's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
HROWM vs SCYX Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SCYX has a market cap of 32.4M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while SCYX trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.51. In terms of profitability, HROWM's ROE is -0.34%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, HROWM is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check SCYX's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
HROWM vs NSRX Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, NSRX has a market cap of 29.4M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while NSRX trades at $3.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas NSRX's P/E ratio is -4.74. In terms of profitability, HROWM's ROE is -0.34%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, HROWM is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check NSRX's competition here
Stablecoin Development Corp. (AMEX: SDEV)
HROWM vs SDEV Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SDEV has a market cap of 27.6M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while SDEV trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SDEV's P/E ratio is -0.18. In terms of profitability, HROWM's ROE is -0.34%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, HROWM is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check SDEV's competition here
Cerenome, Inc. (NASDAQ: CNSY)
HROWM vs CNSY Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CNSY has a market cap of 26.4M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CNSY trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CNSY's P/E ratio is -0.53. In terms of profitability, HROWM's ROE is -0.34%, compared to CNSY's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
HROWM vs BFRI Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, BFRI has a market cap of 15.5M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while BFRI trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -1.13. In terms of profitability, HROWM's ROE is -0.34%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, HROWM is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
HROWM vs CJJD Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CJJD's P/E ratio is -0.46. In terms of profitability, HROWM's ROE is -0.34%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, HROWM is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
HROWM vs SSY Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SSY's P/E ratio is -2.86. In terms of profitability, HROWM's ROE is -0.34%, compared to SSY's ROE of -0.09%. Regarding short-term risk, HROWM is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
HROWM vs POM Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, POM has a market cap of 7.3M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while POM trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas POM's P/E ratio is -0.21. In terms of profitability, HROWM's ROE is -0.34%, compared to POM's ROE of +0.16%. Regarding short-term risk, HROWM is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check POM's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
HROWM vs PAVS Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, PAVS has a market cap of 6.4M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while PAVS trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas PAVS's P/E ratio is -0.08. In terms of profitability, HROWM's ROE is -0.34%, compared to PAVS's ROE of -0.27%. Regarding short-term risk, HROWM is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check PAVS's competition here
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD)
HROWM vs HKPD Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, HKPD has a market cap of 4.6M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while HKPD trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas HKPD's P/E ratio is -6.99. In terms of profitability, HROWM's ROE is -0.34%, compared to HKPD's ROE of -0.14%. Regarding short-term risk, HROWM is less volatile compared to HKPD. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check HKPD's competition here
AIxCrypto Holdings, Inc. (NASDAQ: AIXC)
HROWM vs AIXC Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, AIXC has a market cap of 4.1M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while AIXC trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas AIXC's P/E ratio is -0.09. In terms of profitability, HROWM's ROE is -0.34%, compared to AIXC's ROE of -0.94%. Regarding short-term risk, HROWM is less volatile compared to AIXC. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check AIXC's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
HROWM vs MDVL Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas MDVL's P/E ratio is -0.05. In terms of profitability, HROWM's ROE is -0.34%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, HROWM is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
HROWM vs ATNFW Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ATNFW's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.34%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, HROWM is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
HROWM vs BGMSP Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, HROWM's ROE is -0.34%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, HROWM is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check BGMSP's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
HROWM vs BGMS Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while BGMS trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas BGMS's P/E ratio is -0.25. In terms of profitability, HROWM's ROE is -0.34%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, HROWM is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check BGMS's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
HROWM vs AZNH Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas AZNH's P/E ratio is 38.35. In terms of profitability, HROWM's ROE is -0.34%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, HROWM is less volatile compared to AZNH. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
HROWM vs LFLYW Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, HROWM's ROE is -0.34%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, HROWM is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check LFLYW's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
HROWM vs SBFMW Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SBFMW has a market cap of 175.2K. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while SBFMW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SBFMW's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.34%, compared to SBFMW's ROE of -0.26%. Regarding short-term risk, HROWM is less volatile compared to SBFMW. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check SBFMW's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
HROWM vs ESRX Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ESRX's P/E ratio is 10.69. In terms of profitability, HROWM's ROE is -0.34%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, HROWM is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check ESRX's competition here
POZEN Inc. (NASDAQ: POZN)
HROWM vs POZN Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, POZN has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas POZN's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.34%, compared to POZN's ROE of +0.61%. Regarding short-term risk, HROWM is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check POZN's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
HROWM vs OREX Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, OREX has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas OREX's P/E ratio is -0.14. In terms of profitability, HROWM's ROE is -0.34%, compared to OREX's ROE of -0.54%. Regarding short-term risk, HROWM is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check OREX's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
HROWM vs CPD Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CPD has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CPD's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.34%, compared to CPD's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to CPD. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check CPD's competition here
Shire plc (NASDAQ: SHPG)
HROWM vs SHPG Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SHPG's P/E ratio is 11.35. In terms of profitability, HROWM's ROE is -0.34%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, HROWM is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for HROWM.Check SHPG's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
HROWM vs IPXL Comparison August 2026
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas IPXL's P/E ratio is -10.11. In terms of profitability, HROWM's ROE is -0.34%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, HROWM is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for HROWM.Check IPXL's competition here